PCOS Is More Than Irregular Periods: What PMOS Care Should Include

PCOS has a new name: PMOS

In 2026, polycystic ovary syndrome (PCOS) was renamed polyendocrine metabolic ovarian syndrome (PMOS). The updated name better reflects a condition that can involve reproductive hormones, ovulation, metabolism, skin, mental health and long-term health—not simply ovarian “cysts.”

Patients and search engines will continue to use PCOS during the transition, so both names matter. The name changed; your symptoms, questions and need for individualized care did not.

The symptoms may look unrelated—but they can be connected

Irregular or absent periods may be the first clue. Others notice acne, increased facial or body hair, scalp-hair thinning, difficulty conceiving, weight or metabolic changes, or darkened skin in body folds. Some people have only a few features, and the pattern can change across the lifespan.

These symptoms are not proof of PMOS/PCOS. Thyroid disease, elevated prolactin, pregnancy, hypothalamic causes, medication effects, perimenopause and other endocrine conditions can overlap. A responsible evaluation asks what else could explain the pattern instead of forcing every symptom into one diagnosis.

• Cycles that are persistently long, absent or unpredictable
• Clinical or laboratory signs of higher androgen activity
• Acne, facial or body hair growth, or scalp-hair thinning
• Difficulty identifying ovulation or becoming pregnant
• Insulin resistance, abnormal glucose results or other metabolic concerns
• Sleep, mood or quality-of-life concerns that deserve attention too

Diagnosis is not one ultrasound—or one hormone panel

In adults, current international guidance uses a combination of ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology after other causes are considered. When irregular cycles and hyperandrogenism are already present, an ultrasound or AMH level is not automatically required to establish the diagnosis.

The word “polycystic” created years of confusion. Ovarian follicles are not the same as pathologic ovarian cysts, and some people with PMOS do not have the ultrasound appearance. AMH can add information in selected adults, but it should not be used as a stand-alone diagnostic test. Adolescents require a more cautious, age-specific approach to avoid overdiagnosis.

• A detailed menstrual and symptom history
• Pregnancy testing when relevant
• Assessment for clinical and biochemical androgen excess
• Targeted testing to exclude overlapping conditions
• Metabolic and cardiovascular risk assessment
• Ultrasound or AMH only when it adds needed diagnostic information

Metabolic health deserves care without blame

PMOS can be associated with insulin resistance, impaired glucose regulation, dyslipidemia, sleep apnea and other cardiometabolic risks. Those risks deserve appropriate screening regardless of body size.

Weight stigma is not a treatment plan. Nutrition, movement, sleep and other health behaviors can be useful, but counseling should be realistic, collaborative and free from shame. When medication is appropriate, it should be connected to the person’s symptoms, metabolic findings, reproductive goals and preferences—not offered as a universal protocol.

Fertility changes the treatment conversation

PMOS is a common cause of ovulatory infertility, but it does not mean pregnancy is impossible. The first question is whether ovulation is occurring consistently and whether any additional female or male fertility factors need evaluation in parallel.

Someone trying to conceive needs a different plan than someone primarily seeking cycle control, acne treatment or long-term metabolic risk reduction. Current international guidance identifies letrozole as the first-line medication for ovulation induction in anovulatory infertility due to PMOS when no other infertility factors are present, but treatment selection requires individualized evaluation and prescribing.

Treatment should match the goal—not the package

There is no single PMOS treatment that fits everyone. Combined hormonal contraception may be considered for menstrual irregularity or androgen-related symptoms in appropriate patients. Metformin may be considered for selected metabolic indications. Anti-androgen therapy requires careful counseling, including pregnancy prevention when relevant. Fertility treatment follows a different pathway.

The right plan may also involve dermatology, nutrition support, sleep evaluation, behavioral-health care, reproductive endocrinology or another specialist. Good care explains why an option is being offered, what it can realistically change, what risks or limits apply, and how progress will be reassessed.

• What symptom or health risk are we treating?
• Are pregnancy or future fertility goals part of the decision?
• What alternatives are available?
• What monitoring is appropriate?
• When should another specialist become involved?

When should you seek an evaluation?

You do not need to wait until you are trying to conceive. Persistently irregular or absent periods, new androgen-related symptoms, difficulty becoming pregnant, or metabolic concerns are reasonable reasons to ask for an evaluation now.

For patients in Navarre and nearby Gulf Breeze, the useful starting point is not the largest possible lab panel. It is a focused history, thoughtfully selected testing and a plan that connects cycles, hormones, metabolism and reproductive goals without reducing you to one symptom or one number.